Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ONTY's Cash to Debt is ranked higher than
100% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. ONTY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ONTY' s 10-Year Cash to Debt Range
Min: 5.92  Med: 168.56 Max: No Debt
Current: No Debt
Interest Coverage No Debt
ONTY's Interest Coverage is ranked higher than
100% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONTY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ONTY' s 10-Year Interest Coverage Range
Min: 1060.29  Med: 10000.00 Max: 9999.99
Current: No Debt
1060.29
9999.99
F-Score: 2
Z-Score: 5.40
M-Score: -1.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -56.62
ONTY's ROE (%) is ranked lower than
66% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ONTY: -56.62 )
Ranked among companies with meaningful ROE (%) only.
ONTY' s 10-Year ROE (%) Range
Min: -163.15  Med: -64.39 Max: 45.34
Current: -56.62
-163.15
45.34
ROA (%) -50.63
ONTY's ROA (%) is ranked lower than
68% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. ONTY: -50.63 )
Ranked among companies with meaningful ROA (%) only.
ONTY' s 10-Year ROA (%) Range
Min: -133.9  Med: -48.94 Max: 24.26
Current: -50.63
-133.9
24.26
ROC (Joel Greenblatt) (%) -2933.37
ONTY's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. ONTY: -2933.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ONTY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7802.12  Med: -1775.36 Max: 661.83
Current: -2933.37
-7802.12
661.83
EBITDA Growth (3Y)(%) -16.30
ONTY's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ONTY: -16.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ONTY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -60  Med: -14.40 Max: 26.2
Current: -16.3
-60
26.2
EPS Growth (3Y)(%) -17.00
ONTY's EPS Growth (3Y)(%) is ranked lower than
63% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ONTY: -17.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ONTY' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.4  Med: -16.60 Max: 28.7
Current: -17
-60.4
28.7
» ONTY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ONTY Guru Trades in Q3 2014

Steven Cohen 721,075 sh (New)
Murray Stahl 32,333 sh (unchged)
First Eagle Investment Sold Out
Paul Tudor Jones 22,957 sh (-27.02%)
» More
Q4 2014

ONTY Guru Trades in Q4 2014

Murray Stahl 32,333 sh (unchged)
Steven Cohen 721,075 sh (unchged)
Paul Tudor Jones 22,957 sh (unchged)
» More
Q1 2015

ONTY Guru Trades in Q1 2015

First Eagle Investment 1,300,000 sh (New)
Jim Simons 614,178 sh (New)
Murray Stahl 33,333 sh (+3.09%)
Paul Tudor Jones 22,957 sh (unchged)
Steven Cohen 625,000 sh (-13.32%)
» More
Q2 2015

ONTY Guru Trades in Q2 2015

Paul Tudor Jones 63,257 sh (+175.55%)
Murray Stahl 33,333 sh (unchged)
Steven Cohen Sold Out
First Eagle Investment Sold Out
Jim Simons 474,192 sh (-22.79%)
» More
» Details

Insider Trades

Latest Guru Trades with ONTY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.51
ONTY's P/B is ranked higher than
63% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ONTY: 3.51 )
Ranked among companies with meaningful P/B only.
ONTY' s 10-Year P/B Range
Min: 0.75  Med: 4.31 Max: 23.93
Current: 3.51
0.75
23.93
Current Ratio 12.00
ONTY's Current Ratio is ranked higher than
81% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ONTY: 12.00 )
Ranked among companies with meaningful Current Ratio only.
ONTY' s 10-Year Current Ratio Range
Min: 1.67  Med: 12.24 Max: 36.71
Current: 12
1.67
36.71
Quick Ratio 12.00
ONTY's Quick Ratio is ranked higher than
81% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. ONTY: 12.00 )
Ranked among companies with meaningful Quick Ratio only.
ONTY' s 10-Year Quick Ratio Range
Min: 0.95  Med: 12.24 Max: 36.71
Current: 12
0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.90
ONTY's Price/Net Cash is ranked higher than
63% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. ONTY: 5.90 )
Ranked among companies with meaningful Price/Net Cash only.
ONTY' s 10-Year Price/Net Cash Range
Min: 1.03  Med: 5.43 Max: 38.63
Current: 5.9
1.03
38.63
Price/Net Current Asset Value 5.90
ONTY's Price/Net Current Asset Value is ranked higher than
60% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. ONTY: 5.90 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ONTY' s 10-Year Price/Net Current Asset Value Range
Min: 0.9  Med: 5.20 Max: 38
Current: 5.9
0.9
38
Price/Tangible Book 5.62
ONTY's Price/Tangible Book is ranked higher than
54% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. ONTY: 5.62 )
Ranked among companies with meaningful Price/Tangible Book only.
ONTY' s 10-Year Price/Tangible Book Range
Min: 0.84  Med: 4.65 Max: 81
Current: 5.62
0.84
81
Earnings Yield (Greenblatt) (%) -19.28
ONTY's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ONTY: -19.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ONTY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -22.89  Med: 18.20 Max: 487.4
Current: -19.28
-22.89
487.4

Analyst Estimate

Dec15 Dec16 Dec17
EPS($) -0.37 -0.37 -0.37
EPS without NRI($) -0.37 -0.37 -0.37

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:3O6.Germany,
Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.
» More Articles for ONTY

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
pro-longs life Jul 30 2011 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
cooldecency99 note on ONTY May 01 2010 
creiter note on ONTY Jan 03 2010 

More From Other Websites
Edited Transcript of ONTY earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 21 2015
ONCOTHYREON INC. Financials Aug 15 2015
Cracks Are Starting to Show in China's Great Wall; 4 Stocks in The Defensive Healthcare Sector Worth... Aug 13 2015
10-Q for Oncothyreon, Inc. Aug 08 2015
Oncothyreon reports 2Q loss Aug 06 2015
Oncothyreon reports 2Q loss Aug 06 2015
Oncothyreon Inc Earnings Call scheduled for 4:30 pm ET today Aug 06 2015
ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2015
Oncothyreon Reports Second Quarter 2015 Financial Results Aug 06 2015
Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call Jul 30 2015
Edited Transcript of ONTY earnings conference call or presentation 11-May-15 8:30pm GMT Jul 21 2015
ONCOTHYREON INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 11 2015
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer Jun 07 2015
Top-Performing Biotech and Drug Stocks During ASCO '15 Jun 04 2015
Are Any Of These On Your 'Penny Stocks To Watch' List Jun 01 2015
Oncothyreon (ONTY) Stock Spikes Following Presentation on Breast Cancer Treatment Candidate Jun 01 2015
6 Key Cancer Winners From ASCO Presentations Jun 01 2015
ASCO targets immunotherapy and drug costs Jun 01 2015
Oncothyreon shares rise on study results Jun 01 2015
Oncothyreon shares rise on study results Jun 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK